Gate Neurosciences

Check out our spotlight piece in Drug Discovery World's summer issue! Co-founder Dr. Anantha Shekhar shares perspectives on the challenges and opportunities for neuroplastogen therapies in #mentalhealth

.@GateNeuro and @biosignals illuminate depression biomarkers with EEG bioworld.com/articles/705051 #biotech #pharma

Happy to announce our collab with @biosignals to advance #precisionmedicine in neuropsychiatry! We will be including their Dreem 3S headband in our upcoming zelquistinel Phase 2 trial in MDD to explore novel EEG biomarker endpoints

Excited to partner with @GateNeuro for a Phase 2 trial on zelquistinel to treat major depressive disorder! 🚀 Leveraging FDA-cleared Dreem 3S headband & our AI Analytics, we're bringing precision to psychiatry with novel EEG biomarkers and sleep endpoints! businesswire.com/news/home/2024…

Gate Neurosciences Collaborates with Beacon Biosignals to Leverage EEG Biomarkers in Major Depressive Disorder. Learn more: ow.ly/CqVz50Qu1vO

Our lead program, zelquistinel, was included in a recent review paper from @UTHealthHouston on GABA-glutamate targeted drugs: mdpi.com/1424-8247/16/1… "Future treatment models need to consider nuances of glutamate signaling with regard to timing & duration of action"...we agree!

Nice @TheAtlantic piece on how psychedelics hallucinogenic effects may not drive #mentalhealth outcomes - its the impact on neuroplasticity. Our novel drug candidates can safely enhance plasticity & strengthen neural connections to treat disease from #MDD to #alzheimers & #autism

We're excited to share the latest clinical trial results for our rapid-acting IV antidepressant, apimostinel. These new qEEG #biomarker data reflect NMDAR activation and enhanced synaptic function, to help guide future clinical trials. Link: lnkd.in/eRjJauNj #mentalhealth

Great to see coverage in @WIRED on the link between #neuroplasticity and #depression. Current antidepressants take weeks to work. We are developing a new class of drugs targeting the #glutamate system to rapidly enhance neuroplasticity within hours to days. #mentalhealth

In this article, Gate Neurosciences details their role on taking on depression with event-driven #pharmacology. They also discuss he challenges & promise of NMDA receptor #modulation, the role of EEG #biomarkers in #DrugDevelopment & much more: drugdiscoverytrends.com/gate-neuroscie…

As part of our commitment to #mentalhealth innovation, we recently expanded our research facilities in Evanston! This renewed effort includes advancing translational EEG biomarkers supporting our '-stinel' programs that enhance synaptic function. businesswire.com/news/home/2023…

I will be in Boston next week at the Cowen Healthcare Conference Mar 6-8. Looking forward to seeing everyone. We are making great progress at Gate Neuro and have news forthcoming about our expanded R&D and results from our clinical biomarker study. #neuroscience #mentalheath

The underlying mechanism of ketamine in depression requires downstream NMDAR-activation. New publication from Todd Gould (gouldlab.org) jneurosci.org/content/early/…

Gate Neuro was recently featured in @PsychTimes ! Co-founder Dr. Anantha Shekhar discusses our ongoing biomarker study with apimostinel, a rapid-acting and safe NMDAR modulator in development for acute depressive disorders. #mentalhealth #precisionmedicine bit.ly/3XtKmi7

This week we announced dosing the first patient cohort in a translational EEG biomarker study of apimostinel. Press release: businesswire.com/news/home/2022…

Gate is committed to #mentalhealth innovation. This morning we announced a publication on the novel NMDA mechanism underlying rapid, durable & safe activity with our lead oral program in Phase 2: bit.ly/3fyrGg4 Link to paper in IJNP: bit.ly/3UQqNzg #biotech

We are excited to officially emerge from stealth! A big thanks to our team, investors, and @abbvie and @LillyPad for their partnership in assembling our next-generation CNS portfolio. Learn more about us here: bit.ly/3Kdr5vk #neuroscience #mentalhealth #biotech